Search Result
Results for "
mouse T cells
" in MedChemExpress (MCE) Product Catalog:
6
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
-
- HY-129492
-
GNF4877
1 Publications Verification
|
DYRK
GSK-3
|
Metabolic Disease
|
|
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC50 of 0.66 μM for mouse β (R7T1) cells) .
|
-
-
- HY-P99948
-
|
AMG-596
|
EGFR
CD3
|
Neurological Disease
Cancer
|
|
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
|
-
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
|
|
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .
|
-
-
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
-
-
- HY-120356A
-
|
TAI-95 tosylate
|
NEKs
Apoptosis
|
Cancer
|
|
T-1101 tosylate (TAI-95 tosylate) is the tosylate salt form of T-1101 (HY-120356). T-1101 tosylate is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 tosylate blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 tosylate induces apoptosis in Huh-7. T-1101 tosylate exhibits antitumor efficacy in mouse models .
|
-
-
- HY-P99152
-
|
Muromanab-CD3
|
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
|
-
-
- HY-131140
-
BD750
5 Publications Verification
|
JAK
STAT
|
Inflammation/Immunology
Cancer
|
|
BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .
|
-
-
- HY-P990802
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
-
- HY-N0600
-
|
|
Interleukin Related
IFNAR
NF-κB
|
Inflammation/Immunology
|
|
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .
|
-
-
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
-
- HY-P99129
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
|
-
-
- HY-P990680
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
|
-
-
- HY-P990795
-
|
|
Osteopontin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
-
- HY-P99916
-
|
AMG-427
|
FLT3
CD3
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
|
-
-
- HY-175802
-
|
HYBI-084
|
WDR5
Potassium Channel
|
Inflammation/Immunology
Cancer
|
|
HBI-2375 (HYBI-084) is a brain-penetrant WDR5 inhibitor with an IC50 of 4.48 nM. HBI-2375 binds to the WINR5 and disrupts MLL1-WDR5 protein-protein interactions. HBI-2375 inhibits cancer cells proliferation and shows anti-tumor activity in AML mouse models, and increases tumor CD8 + cytotoxic T lymphocyte infiltration. HBI-2375 inhibits hERG with an IC50 of 17 µM .
|
-
-
- HY-P99124
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .
|
-
-
- HY-154974
-
|
|
Liposome
|
Cancer
|
|
LNP Lipid-8 (11-A-M) is an ionizable single-tail multi-head lipid that can be used as a lipid nanoparticle (LNP) to deliver siRNA to T cells without targeting ligands. LNP Lipid-8 is more selective for T cells than other cell types such as hepatocytes. LNP Lipid-8 selectively delivers siRNA/sgRNA to T cells (especially CD8+ T cells) through endogenous lipid transport pathways, and can enter cells and release RNA through endocytosis to achieve gene silencing. LNP Lipid-8 loaded with GFP siRNA (siGFP) significantly led to GFP gene silencing in mouse models. LNP Lipid-8 showed good efficacy and safety in both cells and animals, without obvious liver targeting and toxicity. LNP Lipid-8 can be used for RNA delivery research in the fields of tumor immunotherapy and T cell-mediated autoimmune diseases .
|
-
-
- HY-P99128
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
|
-
-
- HY-P99123
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Mouse CD28 Antibody (37.51) is an agonistic agonistic CD28-specific antibody derived from the host Syrian Hamster. Anti-Mouse CD28 Antibody (37.51) partially prevents lethal graft-versus-hostdisease (GVHD) by selective depletion of alloreactive T cells in mice .
|
-
-
- HY-144088
-
ZYF0033
2 Publications Verification
HPK1-IN-22
|
MAP4K
|
Inflammation/Immunology
Cancer
|
|
ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
|
-
-
- HY-162655
-
|
|
LPL Receptor
|
Neurological Disease
|
|
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC50 of 51 nM in HeLa cells and a T1/2 of 2.4 h in mouse .
|
-
-
- HY-P99141
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
|
-
-
- HY-162133
-
|
|
STING
Apoptosis
IKK
IFNAR
NF-κB
|
Cancer
|
MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a STING agonist. MSA-2-Pt inducing cell
death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 + and CD8 + T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .
|
-
-
- HY-P990303
-
|
|
Nuclear Factor of activated T Cells (NFAT)
|
Others
|
|
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry .
|
-
-
- HY-106934A
-
|
BCX 34 dihydrochloride
|
Nucleoside Antimetabolite/Analog
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .
|
-
-
- HY-24504
-
-
-
- HY-P10323
-
|
Tumstatin (74-98), human
|
Integrin
FAK
mTOR
Apoptosis
|
Cancer
|
|
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
|
-
-
- HY-P10323A
-
|
Tumstatin (74-98), human TFA
|
Integrin
FAK
mTOR
Apoptosis
|
Cancer
|
|
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
|
-
-
- HY-P990953
-
|
Gen1047
|
CD3
|
Cancer
|
|
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
|
-
-
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
-
- HY-131598C
-
|
6-Thioguanosine-5'-triphosphate tetrasodium
|
Ras
|
Inflammation/Immunology
|
|
6-Thio-GTP (tetrasodium) is a Vav1-Rac inhibitor. 6-Thio-GTP (tetrasodium) inhibits TCR-stimulated T cell proliferation and CD28-mediated T cell survival. 6-Thio-GTP (tetrasodium) has an immunosuppressive effect in a mouse cardiac allograft transplant model and prolongs cardiac allograft survival .
|
-
-
- HY-P5396A
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
-
- HY-P991112
-
|
|
Transmembrane Glycoprotein
|
Infection
|
|
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
-
- HY-P99138
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonal antibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
|
-
-
- HY-P990820
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-4 Antibody (RMT4-53) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-53) can block T cell immunoglobulin and mucin domain 4 (TIM-4). Anti-Mouse TIM-4 Antibody (RMT4-53) can inhibit the engulfment of apoptotic cells and T cell proliferation. Anti-Mouse TIM-4 Antibody (RMT4-53) can be used for the researches of cancer, immunology and metabolic disease, such as MC38 tumor and graft .
|
-
-
- HY-147696
-
|
|
HSP
AMPK
Reactive Oxygen Species (ROS)
|
Cancer
|
|
SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
|
-
-
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
-
- HY-P990264
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4 +, CD8 + T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models .
|
-
-
- HY-P990124
-
|
|
TNF Receptor
NF-κB
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
-
- HY-145239
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .
|
-
-
- HY-106934
-
|
BCX 34
|
Nucleoside Antimetabolite/Analog
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .
|
-
-
- HY-P990115
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
|
-
-
- HY-P99131
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse CD90.2 Antibody (30H12) is an anti-mouse CD90.2 IgG2b antibody inhibitor derived from host Rat. Anti-Mouse CD90.2 Antibody (30H12) can deplete innate lymphoid cells (ILC) and T cells. Anti-Mouse CD90.2 Antibody (30H12) can be used for the researches of infection, inflammation and immunology, such as Yersinia enterocolitica infection and airway inflammation .
|
-
-
- HY-P990261
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD83 Antibody (Michel-17) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD83. Anti-Mouse CD83 Antibody (Michel-17) can block CD83 and inhibit T cells proliferation. Anti-Mouse CD83 Antibody (Michel-17) can be used for the researches of cancer and immunology, such as solid tumor .
|
-
-
- HY-149920
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (Kd=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t1/2>300 min .
|
-
-
- HY-P990123
-
|
|
Transmembrane Glycoprotein
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
|
-
-
- HY-P990803
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
-
- HY-P991307
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
-
-
- HY-NP158D
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Type II Collagen, T Cell Grade, from Mouse is a T-cell dependent antigen with unique immunological features. Type II Collagen, T Cell Grade, from Mouse can be used as a stimulating antigen for T-cells in in vitro culture systems .
|
-
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
-
- HY-120356
-
|
TAI-95
|
Apoptosis
NEKs
|
Cancer
|
|
T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models .
|
-
- HY-185206
-
|
|
PROTACs
Itk
NF-κB
|
Cancer
|
|
BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma .
|
-
- HY-111604
-
|
|
Others
|
Cancer
|
|
Turbinaric acid is a kind of secosqualene carboxylic acid. Turbinaric acid exhibits cytotoxicity against mouse melanoma cells and human colon cancer cells. Turbinaric acid can be used as a chemical marker for T. conoides. Turbinaric acid can be used for research on melanoma and colon cancer .
|
-
- HY-156296
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC50: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .
|
-
- HY-151066
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .
|
-
- HY-P990149
-
|
|
Tyrosinase
|
Cancer
|
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human TYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8 + T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
|
-
- HY-P990179
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonal antibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
|
-
- HY-P990152
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse TIM-4 Antibody (RMT4-54) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-54) reacts with mouse T cell immunoglobulin and mucin domain 4 (TIM-4) and blocks TIM-4 signaling. Anti-Mouse TIM-4 Antibody (RMT4-54) inhibits phagocytosis of apoptotic cells. Anti-Mouse TIM-4 Antibody (RMT4-54) can be used for the researches of immunology and metabolic disease .
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-NP157C
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Type I Collagen, T Cell Grade, from Mouse has unique immunological features and plays an important role in the structure and function of skin, bones, tendons, etc. Type I Collagen, T Cell Grade, from Mouse can be used as a stimulating antigen for T-cells in in vitro culture systems .
|
-
- HY-P990205
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
|
-
- HY-P10382
-
|
|
MHC
|
Inflammation/Immunology
|
|
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .
|
-
- HY-P990159
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonal antibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
|
-
- HY-P99147
-
|
|
CD3
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) is an Armenian Hamster-derived IgG antibody inhibitor, targeting to mouse TCR V gamma 2. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) reacts with an epitope on the delta chain of the mouse Vγ2 TCR (V gamma 2 T cell receptor). Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can deplete γδ T cell. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can be used for the researches of infection and immunology, such as herpes simplex virus-1 (HSV-1) infection .
|
-
- HY-P990137
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-Rat CD28 Antibody (JJ319) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ319) activates T cells in the presence of T cell receptor-stimulation. Anti-Rat CD28 Antibody (JJ319) can be used for the researches of inflammation and immunology, such as transplantation and neuritis .
|
-
- HY-155745
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research .
|
-
- HY-106934AR
-
|
BCX 34 dihydrochloride (Standard)
|
Nucleoside Antimetabolite/Analog
HIV
Reference Standards
|
Infection
Inflammation/Immunology
Cancer
|
|
Peldesine (dihydrochloride) (Standard) is the analytical standard of Peldesine (dihydrochloride). This product is intended for research and analytical applications. Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .
|
-
- HY-170568
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-73 (Compound 37) is an inhibitor for microtubule polymerization with an IC50 of 1.8 μM. Tubulin polymerization-IN-73 arrests the cell cycle at G2/M phase, induces apoptosis in A549 cell, inhibits the proliferation of A549 WT and A549/T resistant cell with IC50 of 0.023 μM and 0.057 μM. Tubulin polymerization-IN-73 exhibits antitumor efficacy in mouse model .
|
-
- HY-P990793
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD) .
|
-
- HY-P990154
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-1/CD365 Antibody (3B3) is a rat-derived IgG2a κ type agonistic antibody, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3B3) enhances T-cell proliferation and responses by forming a stable TIM-1 complex and bringing TIM-1 into the T-cell receptor (TCR)-CD3 complex. Anti-Mouse TIM-1/CD365 Antibody (3B3) can be used for the researches of cancer, inflammation and immunology, such as experimental autoimmune encephalomyelitis, B16 F10 tumor and transplant .
|
-
- HY-P990153
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse TIM-2 Antibody (RMT2-29) is a rat-derived Ig2a λ type antibody inhibitor, targeting to mouse TIM-2. Anti-Mouse TIM-2 Antibody (RMT2-29) reacts with mouse T cell immunoglobulin and mucin domain 2 (TIM-2) and blocks TIM-2 signaling. Anti-Mouse TIM-2 Antibody (RMT2-29) can be used for the research of immunology.
|
-
- HY-P992061
-
|
|
CD3
Calcium Channel
|
Inflammation/Immunology
|
|
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes .
|
-
- HY-P992062
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 + T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .
|
-
- HY-185098
-
|
|
PD-1/PD-L1
Transmembrane Glycoprotein
|
Cancer
|
|
PD1-PDL1-IN-4 (compound 19) is a potent and orally active PD1-PDL1 inhibitor that modulates TIGIT and PD-1 signalling pathways. PD1-PDL1-IN-4 can rescue CD8 + T cell and mouse splenocyte proliferation. PD1-PDL1-IN-4 inhibits tumor growth in a CT26 syngeneic colon adenocarcinoma mouse model. PD1-PDL1-IN-4 can be used for research on colon cancer .
|
-
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
- HY-P992056
-
|
|
Autophagy
|
Cancer
|
|
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 + T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 + T cells strictly depends on the presence of PILRα, and it does not affect CD4 + T cells or T cell development in the thymus, exhibiting high specificity .
|
-
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
- HY-181599
-
|
|
Mitochondrial Metabolism
DNA/RNA Synthesis
Reactive Oxygen Species (ROS)
Apoptosis
Autophagy
Caspase
Bcl-2 Family
Atg8/LC3
|
Cancer
|
|
XAN-5 is a mitochondrial DNA G-quadruplex (mtG4) ligand with a Kd of 3.8 μM. XAN-5 selectively binds and stabilizes mtG4 structures, disrupting mitochondrial gene transcription and DNA replication. XAN-5 triggers mitochondrial dysfunction, ROS overproduction, G0 phase arrest and caspase-dependent apoptosis. XAN-5 inhibits autophagy and induces immunogenic cell death. XAN-5 inhibits tumor growth in a mouse liver cancer model while enhancing tumor-infiltrating CD4 + and CD8 + T cells. XAN-5 targets two cancer resistance mechanisms simultaneously. XAN-5 can be used for the research of liver cancer .
|
-
- HY-182644
-
|
|
Toll-like Receptor (TLR)
NF-κB
TNF Receptor
Interleukin Related
|
Cancer
|
|
SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8 +T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research .
|
-
- HY-P992352
-
|
|
|
|
|
ES005 is an anti-tumor compound and LAG3 inhibitor. ES005 blocks the interactions of LAG3 with MHC-II, LSECtin and FGL1, thereby effectively reversing the LAG3-mediated inhibition of T cell activation and NFAT reporter gene expression. ES005 exhibits significant tumor growth inhibitory effects in syngeneic mouse breast tumor models using humanized LAG3 knock-in mice. ES005 can be used for breast tumor-related research .
|
-
- HY-NP0243
-
|
mouse cyanogen bromide digested peptide 8
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Mouse CB8 of type II collagen (Mouse cyanogen bromide digested peptide 8) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB8 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
-
- HY-NP0243B
-
|
mouse cyanogen bromide digested peptide 11
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Mouse CB11 of type II collagen (Mouse cyanogen bromide digested peptide 11) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB11 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
-
- HY-NP0243A
-
|
mouse cyanogen bromide digested peptide 10
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Mouse CB10 of type II collagen (Mouse cyanogen bromide digested peptide 10) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB10 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
-
- HY-P991824
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- T cells and Foxp3 + regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-181650
-
|
|
mTOR
Akt
Ribosomal S6 Kinase (RSK)
Apoptosis
Autophagy
PI3K
|
Cancer
|
|
T133 is an orally active ATP-competitive mTOR inhibitor with an IC50 of 0.34 nM and a Ki of 0.17 nM. T133 suppresses phosphorylation of AKT, S6K1, and 4EBP1. T133 inhibits cancer cell proliferation and migration, induces apoptosis, cell cycle arrest, and autophagy. T133 exhibits dose-dependent antitumor efficacy in xenograft mouse models. T133 can be used for the research of cancer, such as gastric cancer and lung cancer .
|
-
- HY-183120
-
|
|
FAK
EGFR
Apoptosis
|
Cancer
|
|
EGFR T790M/FAK-IN-2 is an orally active dual FAK and EGFR T790M kinase inhibitor, with an IC50 of 1.03 nM against FAK and an IC50 of 3.89 nM against EGFR T790M. EGFR T790M/FAK-IN-2 exerts antiproliferative effects in drug-resistant cancer cells overexpressing FAK, inducing apoptosis and cell cycle arrest. EGFR T790M/FAK-IN-2 exhibits antitumor activity in a pancreatic cancer xenograft mouse model. EGFR T790M/FAK-IN-2 can be used for the research of pancreatic cancer, breast cancer and non-small cell lung cancer .
|
-
- HY-P992063
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody that binds to CD8α on mouse CD8 + T cells. When used in combination with a non-depleting anti-CD4 antibody, Anti-Mouse CD8α Antibody (YTS 105.18) does not deplete CD8 + T cells, but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used for research on graft rejection. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-149201
-
|
|
VISTA
Interleukin Related
|
Cancer
|
|
VISTA-IN-1 is an orally active VISTA inhibitor. VISTA-IN-1 inhibits the function of VISTA and promotes the secretion of IL-2. VISTA-IN-1 exerts inhibitory effects on mouse melanoma in vivo. VISTA-IN-1 is applicable to melanoma-related research .
|
-
- HY-P991808
-
-
- HY-P991815
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD90.1 Antibody (OX-7) reacts with the mouse and rat CD90.1. CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels, T cells, neurons and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991820
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Anti-Mouse CD45 Antibody (I3/2.3) reacts with the mouse CD45. CD45 plays a key role in T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P991802
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse TCR Beta Antibody (H57-597) reacts with the mouse TCRβ. Anti-Mouse TCR Beta Antibody (H57-597) can be used for the study of T cell-mediated diseases and transplant rejection. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
- HY-P991810
-
-
- HY-P991827
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
- HY-183937A
-
|
|
PROTACs
Phosphatase
STAT
|
Cancer
|
|
PD-305 is a selective PTPN2 PROTAC degrader, with DC50 values of 0.25 nM and 5.11 nM against PTPN2 and PTPN1, respectively. PD-305 enhances IFN-γ-induced STAT1 phosphorylation, inhibits the proliferation of IFN-γ-stimulated colorectal cancer cells, promotes CD8 + T cell activation, enhances the tumor-killing activity of T cells, and suppresses tumor growth in mouse models. PD-305 can be used for the research of colorectal cancer .
|
-
- HY-P991775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Anti-Rat CTLA-4 Antibody (WKH203) reacts with rat CTLA-4. Anti-Rat CTLA-4 Antibody (WKH203) binds to the CTLA-4 protein disrupts the key signaling mechanisms linked to the suppression of T cell activity, triggering T cells readily and enhancing the immune system’s capacity to identify and eliminate cancer. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991814
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse Ly-6C Antibody (7B10) reacts with the mouse Ly-6C. Ly-6C antigens are encoded by a complex multigene family and have primarily been defined as novel T cell-activating determinants. Recommend Isotype Controls: Armenian Hamster IgM .
|
-
- HY-174612
-
|
|
mRNA
|
Inflammation/Immunology
|
|
Human IL27RA mRNA encodes the human interleukin 27 receptor subunit alpha (IL27RA) protein, a protein that is similar to the mouse T-cell cytokine receptor (Tccr) at the amino acid level. IL27RA is predicted to be a glycosylated transmembrane protein.
|
-
- HY-P991765
-
|
|
VISTA
|
Inflammation/Immunology
|
|
Anti-VISTA Antibody (GG8) reacts with human VISTA. Endogenous VISTA has inhibitory effects both as a ligand on APCs and as a receptor on T cells. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P990790
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-D3181
-
|
|
Fluorescent Dye
Caspase
|
Cancer
|
|
CyGbPF is a granzyme B-specific near-infrared fluorescent probe. CyGbPF can be cleaved by granzyme B to remove the peptide cage group, restoring near-infrared fluorescence. CyGbPF passively accumulates in mouse tumors, and its activated fluorescence correlates with granzyme B expression, CD8 + cytotoxic T lymphocyte populations, and CD4 + helper T lymphocyte populations in tumor tissues. CyGbPF is efficiently cleared by the kidneys, enabling the assessment of immune activation via optical urine analysis. CyGbPF allows real-time non-invasive evaluation of cancer immunotherapeutic efficacy in living animals. CyGbPF can be used in research on cancers such as breast cancer. Excitation wavelength/emission wavelength: approximately 658 nm/approximately 717 nm .
|
-
- HY-P990262
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8 + T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD) .
|
-
- HY-P991193
-
|
|
TNF Receptor
|
Cancer
|
|
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
|
-
- HY-P990201
-
|
|
L-Selectin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonal antibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
|
-
- HY-159886
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
MG-C-30 is an orally active agonist for CD27 with an EC50 of 0.84 μM. MG-C-30 activates NK cells and T cell co-stimulatory signals, and enhances immune response. MG-C-30 exhibits antitumor efficacy in mouse EG7-OVA model .
|
-
- HY-P990287
-
|
|
CD1
|
Inflammation/Immunology
|
|
Anti-Mouse CD1d Antibody (19G11) is a rat-derived IgG1 type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (19G11) can neutralize CD1d and inhibit the activation of invariant natural killer T (iNKT) cells. Anti-Mouse CD1d Antibody (19G11) can be used for the researches of inflammation and immunology, such as colitis .
|
-
- HY-137936
-
|
|
Antibiotic
|
Infection
|
|
Terrecyclic acid is a sesquiterpene originally isolated from A. terreus with antibiotic and anticancer activity. It is active against S. aureus, B. subtilis, and M. roseus (MICs=25, 50, and 25 μg/mL, respectively). Terrecyclic acid induces a heat shock response, increases levels of reactive oxygen species (ROS), and inhibits NF-κB activity and cell growth in 3T3-Y9-B12 cells.2 In vivo, terrecyclic acid (0.1, 1, and 10 mg/ml) reduces the number of ascitic fluid tumor cells in a mouse model of P388 murine leukemia.
|
-
- HY-P991854
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-iNKT Cell Antibody (6B11) recognizes an epitope on T cell receptor (TCR) V alpha 24-J alpha 18. Anti-iNKT Cell Antibody is specific for cloned and primary human but not rodent iNKT and the human invariant TCR-α. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991958
-
|
|
CTLA-4
|
Cancer
|
|
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
|
-
- HY-146461
-
|
|
Apoptosis
Caspase
ROS Kinase
|
Cancer
|
|
Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC50s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .
|
-
- HY-P990249
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
|
-
- HY-P991777
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD86/B7-2 Antibody (2D10) reacts with mouse CD86 (B7-2). Anti-Mouse CD86/B7-2 Antibody (2D10) reduces IL-4 production in T cells. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P990243
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonal antibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
|
-
- HY-P990180
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
|
-
- HY-155971
-
|
|
Autophagy
|
Inflammation/Immunology
Cancer
|
|
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .
|
-
- HY-161519
-
|
|
Pyruvate Kinase
|
Inflammation/Immunology
|
|
PKM2 activator 7 (Compd B4) is a PKM2 activator with the AC50 of 0.144 μM. PKM2 activator 7 suppresses DSS (HY-116282C)-induced colitis by inhibiting T cell growth in mouse colitis model .
|
-
- HY-P10439
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
|
-
- HY-P990299
-
|
|
Phosphatase
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor .
|
-
- HY-149666
-
|
|
DGK
|
Cancer
|
|
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) .
|
-
- HY-149667
-
|
|
DGK
|
Cancer
|
|
BMS-332 is a dual DGKα/ζ lipid kinase inhibitor, with IC50s of 5 and 1 nM against DGKα and DGKζ, respectively. BMS-332 enhances the antigen-specific T cell response. BMS-332 reduces the viral load in the liver and spleen when combined with anti-PD-1 in chronic infection models. BMS-332 can be used for the study of T cell immune checkpoint strategy .
|
-
- HY-P990173
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
|
-
- HY-161785
-
|
|
Apoptosis
EGFR
|
Cancer
|
|
EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutation, targets the tumor environment, and induces apoptosis of cancer cells. EGFR-IN-117 inhibits proliferations of H1975, PC-9, and EGFR mutant cells BaF3-EGFR L858R/T790M/C797S and BaF3– C797S/Del19/T790M, with IC50 of 13 nM, 19 nM, 1.2 nM and 1.3 nM, respectively. EGFR-IN-117 exhibits antitumor efficacy in mouse models .
|
-
- HY-P991759
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD86 Antibody (OX-48) recognizes CD86, thereby blocking the binding of CD86 to CD28, and thus inhibiting T cell proliferation. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991761
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-Mouse CXCL10 Antibody (1F11) reacts with the pro-inflammatory CXCL10. Anti-Mouse CXCL10 Antibody (1F11) can be used for neutralization of CXCL10 (in vitro and in vivo) and for inhibition of T cell recruitment in vivo in a range of inflammatory disease models. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
- HY-P1240
-
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
|
-
- HY-P990292
-
|
|
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD132 (common γ chain) Antibody (3E12) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse CD132. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can block IL-2, IL-4 and IL-7. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can inhibit T cells and B cells. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can be used for the researches of cancer, immunology, inflammation and metabolic disease, such as tumor, skin transfer and diabetes .
|
-
- HY-P991829
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse TIM-1/CD365 Antibody (RMT1-10) reacts with mouse T cell immunoglobulin and mucin domain 1 (TIM-1). Anti-Mouse TIM-1/CD365 Antibody (RMT1-10) is effective in promoting allograft survival through blocking TIM-1. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-20457
-
-
- HY-20457G
-
|
|
Toll-like Receptor (TLR)
Bacterial
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-130757
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Remisporine B is a polyketide, that can be isolated from Penicillium sp. ZJ-SY2. Remisporine B exhibits immunosuppressive efficacy, that inhibits concanavalin A (HY-P2149)-induced T-cell proliferation and LPS (HY-D1056)- induced B-cell proliferations of mouse splenic lymphocytes with IC50 of 30.1 µg/mL and 32.4 µg/mL .
|
-
- HY-114648
-
|
|
Bacterial
|
Infection
Cancer
|
|
AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC50 being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties .
|
-
- HY-101096
-
|
MK-8998; CX-8998; JZP385
|
Calcium Channel
|
Neurological Disease
Cancer
|
|
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .
|
-
- HY-170453
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
iHAC is an inhibitor HSP90-anchoring chimera, that covalently binds BRD4 ligand (+)-JQ-1 to HSP90, and inhibits the proliferation of cancer cells. iHAC activates the anti-tumor immune response, inhibits the recurrence and metastasis of 4T1 breast cancer in mouse models .
|
-
- HY-P992060
-
|
|
CD20
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8 + T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury .
|
-
- HY-P990142
-
|
|
MHC
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonal antibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
|
-
- HY-169853
-
|
|
VISTA
|
Inflammation/Immunology
|
|
M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models .
|
-
- HY-124623
-
|
|
Parasite
|
Infection
|
|
DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against Trypanosoma cruzi (T. cruzi) with an IC50 of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC50 > 100 μM). DNDI-8219 can effectively cure chronic T. cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.
|
-
- HY-168384
-
|
|
STING
TNF Receptor
Interleukin Related
CD28
|
Inflammation/Immunology
|
|
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
|
-
- HY-P990807
-
|
|
CD1
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD1d Antibody (20H2 (HB323)) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (20H2 (HB323)) can block CD1d and neutralize invariant natural killer
T (iNKT) cells. Anti-Mouse CD1d Antibody (20H2 (HB323)) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma, L. monocytogenes infection and arthritis .
|
-
- HY-P99140
-
|
|
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse IL-1R Antibody (JAMA-147) is an anti-mouse IL-1R IgG2b antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IL-1R Antibody (JAMA-147) diminishes Spp1hi-TAM-mediated T cell suppression. Anti-Mouse IL-1R Antibody (JAMA-147) can be used for the researches of inflammation, metabolic disease and infection, such as diabetes .
|
-
- HY-P99119
-
|
|
TNF Receptor
Bcl-2 Family
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
|
-
- HY-149916
-
|
|
Adenosine Receptor
|
Cancer
|
|
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
|
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
- HY-182945
-
|
|
Molecular Glues
IKZF Family
HOXA
Interleukin Related
NF-κB
|
Cancer
|
|
IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma .
|
-
- HY-P99123A
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
|
-
- HY-P990237
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
|
-
- HY-P990141
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonal antibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
|
-
- HY-P990250
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonal antibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
|
-
- HY-162643
-
|
|
PD-1/PD-L1
PARP
|
Cancer
|
|
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC50s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with Ki of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .
|
-
- HY-135432
-
|
APD334 arginine
|
LPL Receptor
|
Inflammation/Immunology
|
|
Etrasimod arginine is an orally available S1P receptor modulator that is a potent full agonist of the S1P1 receptor and has partial agonist activity at S1P4. Etrasimod arginine reduces inflammation in a CD4 +CD45RB high T cell-transferred mouse colitis model .
|
-
- HY-134771
-
|
AS1617612
|
STAT
|
Inflammation/Immunology
|
|
YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC50=0.28 nM) without affecting Th1 cell differentiation . YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma .
|
-
- HY-P992005
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatory T cells in the tumor microenvironment, and activates effector T cells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
|
-
- HY-P990534
-
|
K1-70
|
TSH Receptor
|
Endocrinology
Cancer
|
|
Anti-TSHR Antibody (K1-70) is an anti-TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
|
-
- HY-118917
-
|
|
IMPDH
|
Inflammation/Immunology
|
|
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
|
-
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P991328
-
|
|
Notch
|
Cancer
|
|
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
|
-
- HY-122808
-
|
|
mGluR
NF-κB
AP-1
|
Metabolic Disease
|
|
(-)-Camphoric acid is the less active enantiomer of Camphoric acid. Camphoric acid induces glutamate receptor expression. Camphoric acid also significantly induces the activation of NF-κB and AP-1. Camphoric acid significantly stimulates the differentiation of mouse osteoblastic MC3T3-E1 subclone 4 cells. Camphoric acid has weak regulatory function towards glutamate receptors. Camphoric acid can induce mRNA expression of glutamate signaling molecules and activate transcription factors, thereby stimulating osteoblast differentiation .
|
-
- HY-P990236
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
|
-
- HY-P990157
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonal antibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
-
- HY-P990809
-
|
|
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is an agonistic mouse-derived IgG2a κ antibody, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can stimulate 4-1BB signaling and induce T cell mediated antitumor immunity. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease, such as glioblastoma and retrovirus infection .
|
-
- HY-150307
-
|
|
Protein Arginine Deiminase
|
Inflammation/Immunology
|
|
KP-302 (Compound 23) is a selective inhibitor of protein arginine deaminase PAD2 with a Ki of 60 μM. KP-302 also reverses physical disability in the EAE mouse model of multiple sclerosis (MS) and eliminates T cell infiltration in the brain. KP-302 can be studied in research as a disease-modifying agent for MS .
|
-
- HY-123985
-
|
|
Mitochondrial Metabolism
|
Others
|
|
MFN2 agonist-1 (B-A/l) potently stimulates mitochondrial fusion in mitofusin 2 (MFN2)-deficient cells. MFN2 agonist-1 reverses mitochondrial “clumping” (formation of static mitochondrial aggregates) and restores mitochondrial motility in cultured mouse neurons expressing the CMT2A mutant MFN2 T105M.
|
-
- HY-D2620
-
|
|
Photosensitizer
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .
|
-
- HY-P990188
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research .
|
-
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P990175
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
|
-
- HY-169120
-
|
|
Telomerase
|
Cancer
|
|
FKB04 is a telomeric repeat binding factor 2 (TRF2) inhibitor that exerts its antitumor activity by disrupting the telomere maintenance mechanism in liver cancer cells, leading to T-loop defects, telomere shortening, and cellular senescence. Additionally, FKB04 can inhibit tumor growth in a human liver cancer xenograft mouse model (with Huh-7 cells implanted in BALB/c mice). FKB04 can be used in liver cancer research .
|
-
- HY-P990279
-
|
|
CD276/B7-H3
Apoptosis
STAT
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
|
-
- HY-179045
-
|
|
Estrogen Receptor/ERR
Apoptosis
|
Cancer
|
ERα degrader 14 (Compound B7) is a potent ERα degrader. ERα degrader 14 exhibits significantly potent and selective anti-proliferative activity on two ERα-positive breast cancer cell lines (MCF-7 and T47D). ERα degrader 14 induces cell cycle arrest, inhibits cell migration, and induces cell apoptosis. ERα degrader 14 effectively inhibits tumor growth in mouse models. ERα degrader 14 can be used for the study of breast cancer .
|
-
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
- HY-P990215
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-27 p28 Antibody (MM27.7B1) is a mouse-derived anti-mouse IL-27 p28 IgG2a, κ type antibody inhibitor. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) can neutralize IL-27. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) delays CD8+ T cell reconstitution mediated by IL-27 after murine anti-thymocyte globulin (mATG) treatment in BALB/c heart allografts mice models .
|
-
- HY-P990176
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonal antibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
|
-
- HY-P990822
-
|
|
Transmembrane Glycoprotein
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse TIM-1/CD365 Antibody (3D10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can block mouse T cell immunoglobulin and mucin domain 1 (TIM-1) also known as CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can be used for the researches of inflammation, immunology and cardiovascular disease, such as graft-versus-host disease (GVHD), airway inflammation and atherosclerosis .
|
-
- HY-111193
-
|
3-Chloroprocainamide
|
NF-κB
Apoptosis
|
Cancer
|
|
Declopramide (3-Chloroprocainamide) is an orally active antitumor agent, which inhibits proliferation of cancer cells HL60 and K562, and inhibits tumor growth of human brain astrocytoma (T24) in mouse model. Declopramide induces apoptosis, inhibits NF-κB through inhibition of IκBα degradation. Declopramide serves also as chemosensitizer in research .
|
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
- HY-P10650
-
|
|
Ras
|
Cancer
|
|
FAM49B (190-198) mouse is a peptide fragment of FAM49B. FAM49B is a mitochondria-localized protein that regulates mitochondrial fission. FAM49B regulates mitochondrial function and integrity and tumor progression. FAM49B is also a negative regulator in T cell activation, it acts by repressing GTPase Rac activity and modulating cytoskeleton reorganization .
|
-
- HY-179466
-
|
|
Microtubule/Tubulin
Apoptosis
Caspase
|
Cancer
|
|
BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML .
|
-
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-186205
-
|
|
Drug Metabolite
|
Cancer
|
|
(Rac)-EGC-M5 is an orally active metabolite of green tea Catechin (EGC) (HY-N0898). (Rac)-EGC-M5 enhances the activity of CD4 + T cells. (Rac)-EGC-M5 boosts the cytotoxic activity of NK cells in vivo. (Rac)-EGC-M5 can be used in cancer-related research .
|
-
- HY-181877
-
|
|
HDAC
Adenosine Receptor
|
Cancer
|
IHCH-3185 is an orally active class I HDAC inhibitor (HDAC1 IC50 =102.9 nM) and A2AR antagonist (A2AR Ki =7.6 nM). IHCH-3185 reverses immune gene silencing by inducing histone acetylation and blocks the adenosine signaling pathway to relieve T-cell suppression. IHCH-3185 exhibits antiproliferative activity, induces cell cycle arrest, and significantly improves the tumor microenvironment. IHCH-3185 reduces the proportion of regulatory T cells, increases the CD8 +/Treg ratio, and upregulates the expression of key factors such as H2-K1, Cxcl9 and Cxcl10. IHCH-3185 shows significant antitumor potential in CT26 and MC38 mouse tumor models and is suitable for related cancer research .
|
-
- HY-P990864
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
|
-
- HY-163768
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-153793
-
|
DGKζ-IN-1
|
DGK
IFNAR
Interleukin Related
ERK
|
Cancer
|
|
Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .
|
-
- HY-P5295
-
|
|
Fluorescent Dye
|
Others
|
|
Cy3-Ova (323-339) is an Cy3 labled OVA Peptide (323-339) (HY-P0286). Cy3 is a fluorescent dye belonging to the Cyanine family and is a fluorescent light product of Cy5. Cyanine is commonly used in fluorescence microscopy, cell imaging, and molecular biology experiments. OVA Peptide (323-339) represents the T and B cell epitopes of ovalbumin (OVA). OVA Peptide (323-339) has limited immunogenic efficacy in activating OVA-sensitized and attacked mouse spleen cells .
|
-
- HY-P99943
-
|
KN-046
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
|
-
- HY-P990281
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1 λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can deplete CD25+ T cells. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can be used for the researches of immunology and inflammation, such as atopic dermatitis .
|
-
- HY-P990161
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
|
-
- HY-P990255
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
|
-
- HY-P990254
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
|
-
- HY-112863
-
|
|
ROR
|
Inflammation/Immunology
|
|
RORγt inhibitor 3 is an orally active and potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor. RORγt inhibitor 3 shows high binding affinity and inhibitory activity of Th17 cell differentiation. RORγt inhibitor 3 also shows efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models .
|
-
- HY-179712
-
|
|
TrxR
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
As-CA11 is a Thioredoxin reductase (TrxR) inhibitor with an IC50 of 18.7 nM. As-CA11 can induce cancer cells apoptosis and ROS production. As-CA11 can reduce the level of reduced Trx and increase the level of oxidized Trx. As-CA11 demonstrates anti-tumor activity in the 4T1 tumor-bearing mouse model .
|
-
- HY-P990113
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Rat TCR gamma/delta Antibody (V65) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat TCR gamma/delta. Anti-Rat TCR gamma/delta Antibody (V65) can deplete γδ T cells. Anti-Rat TCR gamma/delta Antibody (V65) can be used for the research of immunology .
|
-
- HY-P991336
-
|
INBRX-106; ES-102
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
|
-
- HY-118338
-
|
|
Parasite
|
Infection
|
|
WRR-483 is an analog of K11777, an inhibitor of cruzain, used to inhibit the proliferation of Trypanosoma cruzi in cell culture. WRR-483 can eradicate parasitic infection in an acute Chagas disease mouse model. WRR-483 is an irreversible cysteine protease inhibitor that shows pH-dependent high affinity and potent trypanocidal activity against cruzain and T. cruzi infection, and is expected to inhibit Chagas disease.
|
-
- HY-174086
-
|
|
Glutathione Peroxidase
Ferroptosis
ROS Kinase
PROTACs
|
Cancer
|
|
PROTAC GPX4 degrader-4 is a GPX4 PROTAC degrader (DC50: 5.32 nM). PROTAC GPX4 degrader-4 inhibits the activity of RT4, T24, and J82 cancer cells (IC50 values are 0.09, 2.97, and 7.58 μM, respectively). PROTAC GPX4 degrader-4 increases lipid ROS levels and induces ferroptosis in T24 and RT4 cells. PROTAC GPX4 degrader-4 has antitumor activity in T24 tumor-bearing BALB/c nude mouse model. PROTAC GPX4 degrader-4 can be used for bladder cancer research. (Pink: target protein ligand (HY-N0193); blue: E3 ligase ligand (HY-1035960); black: linker (HY-W013907); E3 ligase ligand + linker (HY-174087)) .
|
-
- HY-P990187
-
|
|
MHC
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection .
|
-
- HY-164503
-
|
NEP010
|
EGFR
|
Cancer
|
|
Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatinib (HY-10261) by improving pharmacokinetics. Neptinib has a significant inhibitory effect on tumor growth in mouse non-small cell lung cancer models with different EGFR mutations. Neptinib has a certain inhibitory effect on the EGFR kinase family, with IC50 values ??of 0.24 nM, 7.25 nM, 0.46 nM and 1.79 nM for EGFR wt, EGFR L858R/T790M, EGFR L858R and EGFR T790M, respectively .
|
-
- HY-P990203
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis .
|
-
- HY-176149
-
|
|
CaMK
MMP
AMPK
Apoptosis
Autophagy
|
Cancer
|
|
Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research .
|
-
- HY-101096R
-
|
MK-8998 (Standard); CX-8998 (Standard); JZP385 (Standard)
|
Calcium Channel
Reference Standards
|
Neurological Disease
Cancer
|
|
Suvecaltamide (Standard) is the analytical standard of Suvecaltamide (HY-101096). This product is intended for research and analytical applications. Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .
|
-
- HY-P10826
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
|
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection .
|
-
- HY-100449
-
AL-8810
1 Publications Verification
|
Prostaglandin Receptor
p38 MAPK
ERK
|
Neurological Disease
Endocrinology
|
|
AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG) .
|
-
- HY-153793A
-
|
DGKζ-IN-1 TFA
|
DGK
IFNAR
Interleukin Related
ERK
|
Cancer
|
|
Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .
|
-
- HY-179615
-
|
|
Apoptosis
Bcl-2 Family
Survivin
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Entadamide A-CO-C12 is an Entadamide A (HY-N12125) derivative with potent anti-cancer activity, particularly against breast cancer cell lines. Entadamide A-CO-C12 promotes apoptosis, suppresses migratory ability, sphere formation, and stem-like cell populations. Entadamide A-CO-C12 inhibits tumor growth in a 4T1 mouse model. Entadamide A-CO-C12 can be used for the research of breast cancer .
|
-
- HY-175846
-
|
|
Drug Derivative
Apoptosis
|
Cancer
|
|
TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer .
|
-
- HY-170551
-
|
|
Carbonic Anhydrase
VEGFR
|
Cancer
|
|
CA IX/VEGFR-2-IN-3 (Compound 6i) is an inhibitor of Carbonic Anhydrase IX and VEGFR-2, with IC50 values of 41 and 48 nM, respectively. CA IX/VEGFR-2-IN-3 exhibits anticancer activity, inhibiting the growth of MCF-7 breast cancer cells (with an IC50 of 22.33 μM) and mouse fibroblast cell line 3T3 (where cell viability is less than 40% at a concentration of 100 μM). CA IX/VEGFR-2-IN-3 can be used for research in the field of cancer treatment .
|
-
- HY-P99144A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .
|
-
- HY-164411
-
|
|
c-Met/HGFR
|
Cancer
|
|
KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models .
|
-
- HY-P991181
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .
|
-
- HY-150724
-
|
1018 ISS
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
|
-
- HY-P990004
-
|
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
|
-
- HY-146561
-
|
|
Glucocorticoid Receptor
NF-κB
|
Inflammation/Immunology
|
|
S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC50 value of 1.92 μM for NF-κB transrepression (TR). S-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. S-HP210 is nontoxic at effective doses against mouse fibroblasts 3T3 cells .
|
-
- HY-116640
-
|
|
AP-1
Nuclear Factor of activated T Cells (NFAT)
AMPK
Autophagy
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders .
|
-
- HY-P991353
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
|
-
- HY-P990160
-
|
|
MHC
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonal antibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
|
-
- HY-P99146
-
|
|
CD3
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonal antibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
|
-
- HY-173060
-
|
|
ERK
Apoptosis
Autophagy
|
Cancer
|
|
ERK1/2 inhibitor 13 (Compound 21y) is the orally active inhibitor for ERK that inhibits ERK1 and ERK2 with IC50 of 91.71 nM and 97.87 nM. ERK1/2 inhibitor 13 inhibits the proliferation of MCF-7, 4T1, MDA-MB-468, and HCC1970 (IC50 of 0.67, 2.76, 2.15 and 1.68 μM), inhibits the cancer cell migration, induces apoptosis and autophagy in MCF-7. ERK1/2 inhibitor 13 exhibits antitumor and anti-metastatic effect in 4T1 xenograft mouse model .
|
-
- HY-P990304
-
|
|
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a rat-derived IgG2a κ antibody inhibitor, targeting to mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can block 4-1BB ligand (4-1BBL) and inhibit CD4 + and CD8 + T cells. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology, such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection and herpetic stromal keratitis (HSK) .
|
-
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
-
- HY-160215A
-
|
|
TGF-β Receptor
p38 MAPK
TGF-beta/Smad
Interleukin Related
|
Cancer
|
|
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
|
-
- HY-P990819
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-Rat CD28 Antibody (JJ316) is a mouse-derived agonistic IgG1 κ type antibody, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ316) can induce T cell proliferation. Anti-Rat CD28 Antibody (JJ316) can be used for the researches of inflammation, immunology and neurological disease, such as experimental autoimmune encephalomyelitis (EAE) and graft-versus-host disease (GvHD) .
|
-
- HY-P992043
-
|
ANK-101
|
Interleukin Related
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tolododekin alfa (ANK-101) is a drug conjugate that anchors and combines IL-12 with Aluminum Hydroxide (HY-B1521). Tolododekin alfa promotes the recruitment of effector CD8 + T cells to tumor sites, enhances the production of γ-interferon, upregulates the expression of PD-L1, and induces sustained pro-inflammatory gene expression in mouse tumor models. Tolododekin alfa can be used for research related to advanced solid tumors .
|
-
- HY-18676B
-
|
OSU-T315 analog
|
Integrin
Autophagy
Apoptosis
Caspase
PDHK
|
Cancer
|
|
ILK-IN-2 (OSU-T315 analog) is an oral PDK2 inhibitor and also an ILK inhibitor, with an IC50 of 0.6 μM. ILK-IN-2 induces cell autophagy and apoptosis, showing anti-tumor activity. ILK-IN-2 directly abolishes AKT activation by preventing AKT from translocating to lipid rafts, triggering Caspase-dependent apoptosis in chronic lymphocytic leukemia (CLL) and extending the lifespan in TCL1 mouse models .
|
-
- HY-P10509
-
|
|
CMV
|
Infection
|
|
IE1 peptide refers to an antigenic peptide encoded by the immediate early (IE) gene of mouse cytomegalovirus (mCMV). IE1 peptide is one of the key antigenic peptides expressed during mCMV infection, plays a role in transcriptional activation in the life cycle of mCMV, and is one of the earliest genes expressed in the viral replication cycle. IE1 peptide is an important target for CD8+ T cell response and can be used to study the host immune response to mCMV infection .
|
-
- HY-P990865
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonal antibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-160215
-
|
|
TGF-β Receptor
p38 MAPK
TGF-beta/Smad
Interleukin Related
|
Cancer
|
|
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
|
-
- HY-P990860
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1 κ chimeric agonistic antibody, targeting to human CD40. Anti-CD40 Antibody (G28.5) can activate CD40 signaling and promote anti-tumor T cell responses. Anti-CD40 Antibody (G28.5) can be used for the research of cancer, such as endometrial cancer .
|
-
- HY-121619
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC50 is 11.8 μM), LNCaP (IC50 is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.
|
-
- HY-157343
-
|
|
Apoptosis
Mitochondrial Metabolism
Caspase
|
Neurological Disease
Cancer
|
|
GD3 Ganglioside is an Apoptosis inducer and a biomarker for mouse neural stem cells. GD3 Ganglioside expresses in neural stem cells and the subventricular zone of the adult mouse brain. GD3 Ganglioside targets the mitochondrial permeability transition pore complex, induces pore opening, dissipates mitochondrial transmembrane potential, triggers Mitochondrial swelling, releases pro-apoptotic factors, and activates Caspase-9. GD3 Ganglioside is applicable to research related to glioblastoma .
|
-
- HY-182802
-
|
|
Ferroptosis
Glutathione Peroxidase
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
|
Cancer
|
|
Ferroptosis inducer-15 is a ferroptosis inducer. Ferroptosis inducer-15 downregulates GPX4 expression, triggers lipid peroxidation via ROS accumulation, and disrupts mitochondrial membrane potential to drive ferroptosis. Ferroptosis inducer-15 increases splenic CD4 + T cell proportion, promotes CD8 + cytotoxic T cell tumor infiltration, and activates antitumor immune responses. Ferroptosis inducer-15 exerts antiproliferative activity against colorectal cancer cells and inhibits tumor growth in xenograft mice models without significant body weight loss. Ferroptosis inducer-15 can be used for the research of cancer, such as colorectal cancer .
|
-
- HY-172934
-
|
|
Toll-like Receptor (TLR)
NO Synthase
PROTACs
|
Inflammation/Immunology
Cancer
|
|
FGT-4 is a folate receptor β (FR-β) targeting chimeric molecule. FGT-4 is a TLR7 agonist. FGT-4 facilitates the secretion of iNOS and proinflammatory cytokine IL-6 associated with M1 macrophages and enhances the proliferation of cytotoxic CD8 + T cells. FGT-4 has anti-tumor activity in the 4T1 breast cancer mouse model. FGT-4 can be used for the study of cancer immunity. (Pink: target protein TLR7/8 agonist 1 ligand (HY-103698); black: linker (HY-172936); blue: FR-β ligand (HY-172935)) .
|
-
- HY-P991461
-
|
XmAb968
|
CD38
|
Cancer
|
|
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
|
-
- HY-175857
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .
|
-
- HY-152830
-
|
Q702
|
c-Fms
TAM Receptor
MHC
|
Cancer
|
|
Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
|
-
- HY-165484
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .
|
-
- HY-181924
-
|
|
MAP4K
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
HPK1-IN-68 (Compound 39) is a HPK1 inhibitor with an IC50 of 2.8 nM. HPK1-IN-68 blocks HPK1 signaling, inhibits HPK1-mediated phosphorylation of SLP76, and promotes the production of the IL-2 cytokine. HPK1-IN-68 antagonizes the immunosuppressive effect mediated by PGE2. HPK1-IN-68 enhances the infiltration of CD3 +/CD8 + T cells into tumor tissues. HPK1-IN-68 exerts T cell-dependent antitumor efficacy in a mouse colon cancer model. HPK1-IN-68 exhibits significant synergistic antitumor effects when used in combination with anti-PD-1. HPK1-IN-68 is applicable to research related to colon cancer .
|
-
- HY-P1837
-
|
|
Influenza Virus
HSV
|
Infection
|
|
Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K d to form a complex, which is then recognized by specific CD8 + T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8 + T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza .
|
-
- HY-170336
-
|
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
|
PROTAC ERα Degrader-10 (Compound 160a) is an orally active degrader for ERα with DC50 of 0.37-1.1 nM, in cells MCF7, T47D and CAMA-1. PROTAC ERα Degrader-10 exhibits antitumor efficacy in mouse model . (Pink: ligand for target protein (HY-170339); Black: linker (HY-30105); Blue: ligand for E3 ligase Cereblon (HY-168055))
|
-
- HY-155195
-
|
|
FLT3
|
Cancer
|
|
FLT3/CHK-IN-1 (Compound 18) is a dual inhibitor of FLT3/CHK1. FLT3/CHK-IN-1 is more than 1700 times more selective to c-KI T and greatly reduces hERG affinity with an IC50 value of 58.4 μM. FLT3/CHK-IN-1 inhibits tumor growth in mouse xenotransplantation models inoculated with MV-4-11 cells .
|
-
- HY-161954
-
|
|
HDAC
|
Cancer
|
|
HDAC8-IN-12 (compound 5k) is a non-hydroxamic acid, selective inhibitor of HDAC8 (IC50: 0.12 nM) and a potent inhibitor of breast cancer. HDAC8-IN-12 triggers anti-tumor immunity by activating T cells, increasing the proportion of M1 macrophages and decreasing the proportion of M2 macrophages. HDAC8-IN-12 (50 mg/kg) exerts tumor suppressive effects in an orthotopic mouse model of breast cancer .
|
-
- HY-P1997
-
|
Desferrichrome; DFC; N-Desferriferrichrome
|
Biochemical Assay Reagents
|
Others
|
|
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
|
-
- HY-130743
-
|
Bis-eugenol; Dehydrodieugenol
|
Parasite
|
Infection
|
|
Dieugenol is a neolignan that has been found in N. leucantha and has antioxidative and antiprotozoal activities. It inhibits the formation of thiobarbituric acid reactive substances (TBARS) and scavenges superoxide anions, but not hydroxyl radicals, in cell-free assays. It has anti-trypanosomal activity against T. cruzi amastigotes and trypomastigotes (IC50s=15.1 and 11.5 μM, respectively) but is cytotoxic to NCTC L-929 fibroblasts with a 50% cytotoxic concentration (CC50) value of 58.2 μM.2 Dieugenol (15 μM) disrupts the integrity of the T. cruzi trypomastigote plasma membrane but does not induce the production of reactive oxygen species (ROS) in trypomastigotes or LPS-stimulated and unstimulated isolated mouse peritoneal macrophages.
|
-
- HY-159912
-
|
|
YAP
|
Cancer
|
|
pan-TEAD-IN-1 (Compound 3) is an orally active pan-TEAD inhibitor targeting the palmitoylation site of TEAD, disrupting its interaction with the coactivators YAP/TAZ, thereby suppressing the transcriptional upregulation of oncogenes (e.g., Ctgf and Cyr61) in the Hippo signaling pathway. pan-TEAD-IN-1 exhibits excellent activity with a luciferase IC50 of 0.36 nM and an H226 cell IC50 of 1.52 nM. It also shows favorable pharmacokinetics (AUC0–∞ = 228.7 μg/mL·min, T1/2 = 183.9 min). In TEAD-dependent xenograft mouse models, pan-TEAD-IN-1 significantly inhibited tumor growth, showing promise for research in TEAD-dependent cancers .
|
-
- HY-13757AS1
-
|
ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3
|
Isotope-Labeled Compounds
Estrogen Receptor/ERR
Apoptosis
Autophagy
HSP
|
Cancer
|
|
Tamoxifen-d3 is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-152830A
-
|
Q702 TFA
|
c-Fms
TAM Receptor
MHC
|
Cancer
|
|
Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
|
-
- HY-163767
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-161641
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-62 (Compound 14b) is an inhibitor for microtubule polymerization (IC50 is 7.5 μM) and a degrader for α- and β-tubulin. Tubulin polymerization-IN-62 inhibits proliferation of cancer cells MCF-7, A549 and HCT-116, with IC50 of 32, 60 and 29 nM, respectively. Tubulin polymerization-IN-62 arrests the cell cycle at G2/M phase, inhibits the migration of MCF-7. Tubulin polymerization-IN-62 exhibits antitumor efficacy with a tumor growth inhibition rate (TGI) of 74.27% in 4T1 homograft mouse model .
|
-
- HY-P990870
-
|
|
CD19
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-174830
-
|
|
PD-1/PD-L1
|
Cancer
|
|
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with Kd values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy .
|
-
- HY-P3742
-
|
|
Tyrosinase
MHC
|
Cancer
|
|
Tyrosinase (192-200), human mouse is a HLA-B*4403-restricted tyrosinase epitope with affinity for HLA-B4403 and HLA-B4402. Tyrosinase (192-200), human mouse binds to HLA-B*4403 to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402 donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .
|
-
- HY-P99976
-
|
|
CD19
|
Inflammation/Immunology
|
|
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells .
|
-
- HY-149760
-
|
|
PROTACs
Phosphatase
IFNAR
STAT
|
Cancer
|
|
PVD-06 is a selective PROTAC PTPN2 degrader with a DC50 of 217 nM (selectivity index >60-fold over PTP1B). PVD-06 induces PTPN2 degradation via a VHL-, ubiquitin, and proteasome-dependent pathway. PVD-06 can promote T cell activation and amplify IFN-γ-mediated anticancer activity. PVD-06 can be used to further investigate PTPN2 in diseases such as leukemia and melanoma .
|
-
- HY-13757AR
-
|
ICI 47699(Standard); (Z)-Tamoxifen(Standard); trans-Tamoxifen (Standard)
|
Reference Standards
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Endocrinology
Cancer
|
|
Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A). This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-111310
-
ML351
2 Publications Verification
|
Lipoxygenase
|
Neurological Disease
Metabolic Disease
|
|
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .
|
-
- HY-155848
-
|
|
Phosphatase
|
Cancer
|
|
LYP-IN-4 (compound D14) is a reversible and selective inhibitor of lymphotyrosine phosphatase (LYP) (Ki=1.34 μM, IC50=3.52μM). LYP-IN-4 inhibits LYP to regulate TCR signaling, up-regulates PD-1/PD-L1 expression, and enhance anti-tumor immunity. LYP-IN-4 activates T cells and inhibits M2 macrophage polarization, inhibits tumor growth in MC38 isogenic mouse models.
|
-
- HY-P990801
-
|
|
Integrin
Parasite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P10393
-
|
ERα (295-311)
|
Apoptosis
|
Cancer
|
|
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .
|
-
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
|
-
- HY-165564
-
|
|
Drug Derivative
|
Inflammation/Immunology
|
|
SM-8849 is a thiazole derivative with anti-arthritis activity. SM-8849 specifically targets and inactivates T cells involved in delayed-type hypersensitivity (DTH) reactions, thereby inhibiting the core immunopathological process of arthritis, but has little effect on the humoral immune process such as antibody production. In a mouse arthritis model induced by Type II Collagen (HY-NP003), SM-8849 significantly alleviated clinical symptoms, reduced bone destruction and joint damage. SM-8849 can be used for the study of autoimmune diseases such as rheumatoid arthritis .
|
-
- HY-162644
-
|
|
PD-1/PD-L1
PARP
|
Cancer
|
|
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .
|
-
- HY-175820
-
|
|
VEGFR
ERK
Apoptosis
EGFR
|
Cancer
|
|
AGW-11 is a potent dual inhibitor of EGFR (IC50 = 556 nM) and VEGFR2 (IC50 = 289.7 nM). AGW-11 induces apoptosis and suppresses phosphorylation of EGFR, VEGFR2, and ERK1/2 in HUVECs. AGW-11 effectively inhibits cancer cell growth, reduces HUVEC proliferation, tube formation, and invasion, thereby blocking angiogenesis. AGW-11 significantly suppresses tumor growth and decreases lung metastasis in a 4T1 xenograft mouse model. AGW-11 can be used for the study of breast cancer .
|
-
- HY-109061R
-
|
YH25448 (Standard); GNS-1480 (Standard)
|
Apoptosis
Akt
TRP Channel
EGFR
ERK
Reference Standards
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Lazertinib (Standard) is the analytical standard of Lazertinib (HY-109061). This product is intended for research and analytical applications. Lazertinib (YH25448) is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib can be used in the study of non-small cell lung cancer .
|
-
- HY-109061BR
-
|
YH25448 mesylate (Standard); GNS-1480 mesylate (Standard)
|
Reference Standards
|
Cancer
|
|
Lazertinib mesylate (Standard) is the analytical standard of Lazertinib (mesylate) (HY-109061B). This product is intended for research and analytical applications. Lazertinib (YH25448) mesylate is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib mesylate inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib mesylate can be used in the study of non-small cell lung cancer .
|
-
- HY-161778
-
|
|
HDAC
VD/VDR
|
Inflammation/Immunology
Cancer
|
|
ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization .
|
-
- HY-N16021
-
|
|
Toll-like Receptor (TLR)
Cdc42-binding kinase
Galectin
|
Inflammation/Immunology
|
|
4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .
|
-
- HY-13757S
-
|
ICI 46474-d3 hydrochloride; (Z)-Tamoxifen-d3 hydrochloride; trans-Tamoxifen-d3 hydrochloride
|
Apoptosis
Estrogen Receptor/ERR
Autophagy
HSP
Isotope-Labeled Compounds
|
Cancer
|
|
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-13757R
-
|
ICI 46474 (Standard); (Z)-Tamoxifen Citrate (Standard); trans-Tamoxifen Citrate (Standard)
|
Reference Standards
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Cancer
|
|
Tamoxifen (Citrate) (Standard) is the analytical standard of Tamoxifen (Citrate). This product is intended for research and analytical applications. Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-179578
-
|
|
Enolase
AMPK
Autophagy
Apoptosis
mTOR
Caspase
|
Metabolic Disease
Cancer
|
|
SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease .
|
-
- HY-P991481
-
|
|
CCR
|
Inflammation/Immunology
Cancer
|
|
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 + regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .
|
-
- HY-170928
-
|
|
EGFR
Anaplastic lymphoma kinase (ALK)
Cytochrome P450
|
Cancer
|
|
DA-0157 is the orally active inhibitor for EGFR and ALK that overcomes drug-resistant mutations of EGFR C797S and ALK in NSCLC) cells. DA-0157 inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50 = 6.9 nM), Ba/F3-EGFR WT (IC50 = 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50 = 5.5 nM), and Ba/F3-EML4-ALK (IC50 = 7.4 nM). DA-0157 inhibits CYP2D6 with IC50 of 5.26 μM. DA-0157 exhibits antitumor efficacy in mouse models .
|
-
- HY-119024
-
|
|
SHP1
STAT
|
Cancer
|
|
BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 + T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields .
|
-
- HY-177338
-
|
|
STING
Cyclic GMP-AMP Synthase
IFNAR
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
|
-
- HY-183866
-
|
Maleimide-KGDEVD-doxorubicin
|
Peptide-Drug Conjugates (PDCs)
HSP
IFNAR
|
Cancer
|
|
MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8 + T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer .
|
-
- HY-159771
-
|
|
FAP
|
Cancer
|
|
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
|
-
- HY-P990868
-
|
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
- HY-162874
-
|
|
STING
IFNAR
|
Cancer
|
|
diABZI-V/C-DBCO is a STING agonist with an EC50 of 1.47 nM. diABZI-V/C-DBCO activates the STING pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B + CD8 + T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .
|
-
- HY-18940
-
|
Cilo
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Cilobradine (Cilo) is a HCN channel blocker with heart rate reducing activity. Cilobradine blocks the slow inward current of human HCN1, HCN2, HCN3, and HCN4 channels. Cilobradine has a slightly higher efficiency in blocking endogenous If in mouse sinoatrial node cells (IC50 value is 0.62μM). Cilobradine can dose-dependently reduce the heart rate from 600 to 200 bpm with an ED50 value of 1.2 mg/kg. Cilobradine induces arrhythmias at doses greater than 5 mg/kg, which are characterized by periodic fluctuations between T waves and P waves .
|
-
- HY-P990128
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD80/B7-1. Anti-Rat CD80/B7-1 Antibody (3H5) blocks a costimulatory signals for T-cell activation. Anti-Rat CD80/B7-1 Antibody (3H5) can be used for the researches of cancer and immunology .
|
-
- HY-181875
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1PR1/S1PR5 agonist-1 (Compound 19) is an orally active S1PR1 and S1PR5 agonist with EC50 values of 40.0 and 22.9 nM, respectively. S1PR1/S1PR5 agonist-1 binds to key residues of S1PR1 to mediate agonistic activity. S1PR1/S1PR5 agonist-1 alleviates colitis pathological changes in DSS-induced mouse models and exerts minimal effects on mouse heart rate. S1PR1/S1PR5 agonist-1 can be used for the research of inflammatory bowel disease .
|
-
- HY-P1745
-
|
Insulin B chain (9-23)
|
MHC
Insulin Receptor
IFNAR
|
Inflammation/Immunology
|
|
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
|
-
- HY-182366
-
|
|
Histone Methyltransferase
|
Neurological Disease
Inflammation/Immunology
|
|
EED-IN-5 is an orally active, EZH2-selective trisubstituted pyridine-based EED-H3K27me3 inhibitor and immunomodulator with anti-inflammatory activity. The IC50 value of EED-IN-5 against EED is 28.21 nM. In mouse models, EED-IN-5 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-5 decreases the infiltration of specific dendritic cells, macrophages and T cells into the spinal cord and brain. EED-IN-5 exhibits hERG inhibitory activity, shows negative results in the Mini-Ames test, and causes no obvious toxicity upon long-term high-dose administration. EED-IN-5 can be used for the research of multiple sclerosis .
|
-
- HY-182238
-
|
|
MAP4K
Interleukin Related
|
Cancer
|
|
HPK1-IN-69 is an orally active HPK1 inhibitor with an IC50 of 1.7 nM. HPK1-IN-69 inhibits the HPK1-mediated TCR signaling pathway, reduces the phosphorylation level of SLP76, and promotes the release of IL-2. HPK1-IN-69 exhibits in vivo anti-tumor activity in mouse models. HPK1-IN-69 can be used for the research of colorectal cancer and MC38 syngeneic tumors .
|
-
- HY-169864
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .
|
-
- HY-183784
-
|
|
P2X Receptor
FAK
MMP
|
Cancer
|
|
P2X7R antagonist-1 is an orally active P2X7 receptor antagonist with an IC50 of 3.57 μM. P2X7R antagonist-1 inhibits the proliferation, invasion and metastasis abilities of cancer cells. P2X7R antagonist-1 downregulates the expression of FAK and MMP-9. P2X7R antagonist-1 suppresses tumor growth and metastasis in a mouse breast cancer model. P2X7R antagonist-1 promotes the activation of CD4 and CD8 T cells. P2X7R antagonist-1 can be used in breast cancer-related research .
|
-
- HY-179047
-
|
|
Toll-like Receptor (TLR)
MyD88
IKK
p38 MAPK
ERK
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 +T cells. SMU-L11-R shows potential in colorectal cancer studies .
|
-
- HY-175236
-
|
|
PD-1/PD-L1
Apoptosis
ERK
JNK
Cadherin
p38 MAPK
GSK-3
IFNAR
Caspase
Bcl-2 Family
|
Cancer
|
|
SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research .
|
-
- HY-178716
-
|
|
Phosphatase
IFNAR
STAT
JAK
|
Cancer
|
|
PTPN2/1-IN-4 (Compound WS35) is an orally active, dual-functional inhibitor of PTPN1 and PTPN2 with IC50s of 12.8 and 5.8 nM for PTPN1 and PTPN2, respectively. PTPN2/1-IN-4 modulates the IFNγ-JAK-STAT signaling pathway and significantly augments CD8+ T-cell tumor infiltration. PTPN2/1-IN-4 has potent anticancer activity, robustly inhibiting tumor growth both as a monotherapy and in combination with an anti-PD-1 antibody in B16-OVA syngeneic mouse models .
|
-
- HY-P9996
-
|
LY3434172; IBI-318
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
|
-
- HY-N18070
-
|
|
Drug Derivative
PKC
Fungal
|
Cardiovascular Disease
Infection
Inflammation/Immunology
Cancer
|
|
12-Deoxyphorbol-13-isobutyrate-20-acetate is a 12-deoxy-phorbol diterpene ester. 12-Deoxyphorbol-13-isobutyrate-20-acetate is a protein kinase C (PKC) agonist that activates protein kinase C to phosphorylate troponin I and troponin T. 12-Deoxyphorbol-13-isobutyrate-20-acetate induces skin irritation and necrosis in mice without cocarcinogenic activity. 12-Deoxyphorbol-13-isobutyrate-20-acetate inhibits Aspergillus carbonarius growth. 12-Deoxyphorbol-13-isobutyrate-20-acetate supports research on heart failure, cardiomyopathies and fungal infection .
|
-
- HY-P990869
-
|
|
CD1
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991961
-
|
|
CTLA-4
|
Cancer
|
|
REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
|
-
- HY-182239
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PDL1 degrader-3 (compound e24) is a DUBTAC-like PD-L1 degrader. PDL1 degrader-3 inhibits CSN5 enzymatic activity, increases PD-L1 ubiquitination, and induces PD-L1 degradation via the ubiquitin-proteasome pathway, reducing PD-L1 expression on tumor cell membranes. PDL1 degrader-3 blocks PD-1/PD-L1 interaction, activates the tumor immune microenvironment, enhances tumor-infiltrating T-cell immunity, and inhibits activation of immunosuppressive MDSCs and Tregs. PDL1 degrader-3 exerts antitumor effects in mouse tumor models. PDL1 degrader-3 can be used for the research of colorectal cancer, lung cancer .
|
-
- HY-178032
-
|
|
PARP
Apoptosis
Reactive Oxygen Species (ROS)
DNA/RNA Synthesis
STING
|
Cancer
|
|
PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active PARP1 inhibitor (IC50 = 0.6 nM), and also inhibits PARP2 (IC50 = 1.0 nM) and PARP7 (IC50 = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy .
|
-
- HY-160406
-
|
|
STING
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
SNX281 is a selective STING agonist, with IC50 values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING-dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer .
|
-
- HY-177300
-
|
|
Toll-like Receptor (TLR)
HBV
IFNAR
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
|
-
- HY-180200
-
|
|
Ras
ERK
|
Cancer
|
|
RNK08954 is an orally active KRASG12D inhibitor with a Kd of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRASG12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRASG12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .
|
-
- HY-P990855
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-156096
-
|
|
HDAC
Histone Methyltransferase
Caspase
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
|
-
- HY-185207
-
|
|
Pyroptosis
|
Infection
Cancer
|
|
CQ80 is a PEPD/XPNPEP1 inhibitor and selective CARD8 inflammasome activator. CQ80 has IC50 values of 0.91 μM for PEPD, 43 μM for XPNPEP1. CQ80 promotes the accumulation of Xaa-Pro peptides by inhibiting PEPD and XPNPEP1, releases the fragment of CARD8 for inflammasome formation, and induces pyroptosis via GSDMD cleavage. CQ80 can be used for research on inflammasome, CARD8-expressing cancer cells, HIV-1-infected cell clearance, acute myeloid leukemia (AML) .
|
-
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
- HY-162275
-
|
|
Histone Demethylase
Histone Methyltransferase
STAT
|
Cancer
|
|
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
|
-
- HY-165613
-
|
Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine
|
Toll-like Receptor (TLR)
Influenza Virus
NF-κB
|
Infection
Inflammation/Immunology
|
|
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection .
|
-
- HY-112817
-
|
8-Oxo-Deoxyguanosine triphosphate
|
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
|
-
- HY-132184
-
|
5,6-EET; (±)5,6-EpETrE
|
Adrenergic Receptor
Calcium Channel
|
Endocrinology
|
|
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
|
-
- HY-N17771
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC50=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC50 of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.
|
-
- HY-112817A
-
|
8-Oxo-Deoxyguanosine triphosphate trisodium
|
Apoptosis
|
Others
|
|
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
|
-
- HY-P991896
-
|
AT14-012
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-20457G
-
|
|
Fluorescent Dyes
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-D2620
-
|
|
Fluorescent Dyes
|
|
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .
|
-
- HY-D3181
-
|
|
Fluorescent Dyes
|
|
CyGbPF is a granzyme B-specific near-infrared fluorescent probe. CyGbPF can be cleaved by granzyme B to remove the peptide cage group, restoring near-infrared fluorescence. CyGbPF passively accumulates in mouse tumors, and its activated fluorescence correlates with granzyme B expression, CD8 + cytotoxic T lymphocyte populations, and CD4 + helper T lymphocyte populations in tumor tissues. CyGbPF is efficiently cleared by the kidneys, enabling the assessment of immune activation via optical urine analysis. CyGbPF allows real-time non-invasive evaluation of cancer immunotherapeutic efficacy in living animals. CyGbPF can be used in research on cancers such as breast cancer. Excitation wavelength/emission wavelength: approximately 658 nm/approximately 717 nm .
|
| Cat. No. |
Product Name |
Type |
-
- HY-NP158D
-
|
|
Biochemical Assay Reagents
|
|
Type II Collagen, T Cell Grade, from Mouse is a T-cell dependent antigen with unique immunological features. Type II Collagen, T Cell Grade, from Mouse can be used as a stimulating antigen for T-cells in in vitro culture systems .
|
-
- HY-20457G
-
|
|
Biochemical Assay Reagents
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-NP157C
-
|
|
Biochemical Assay Reagents
|
|
Type I Collagen, T Cell Grade, from Mouse has unique immunological features and plays an important role in the structure and function of skin, bones, tendons, etc. Type I Collagen, T Cell Grade, from Mouse can be used as a stimulating antigen for T-cells in in vitro culture systems .
|
-
- HY-NP0243
-
|
mouse cyanogen bromide digested peptide 8
|
Biochemical Assay Reagents
|
|
Mouse CB8 of type II collagen (Mouse cyanogen bromide digested peptide 8) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB8 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
-
- HY-NP0243B
-
|
mouse cyanogen bromide digested peptide 11
|
Biochemical Assay Reagents
|
|
Mouse CB11 of type II collagen (Mouse cyanogen bromide digested peptide 11) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB11 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
-
- HY-NP0243A
-
|
mouse cyanogen bromide digested peptide 10
|
Biochemical Assay Reagents
|
|
Mouse CB10 of type II collagen (Mouse cyanogen bromide digested peptide 10) is a cyanobromide digested peptide (CB-peptide) fragment of type II collagen, which can be used to study B cell and T cell epitopes of type II collagen. This product is pepsin-free, making it ideal for studying T cell epitope specificity through proliferation assays. Mouse CB10 of type II collagen can also be used as an antigen for analyzing antibody epitope specificity via ELISA .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1240
-
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
|
-
- HY-P1240B
-
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate
|
Peptides
|
Neurological Disease
Inflammation/Immunology
|
|
MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate is a minor component of CNS myelin. MOG (35-55) (acetate) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (acetate) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (acetate) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
|
-
- HY-P1745
-
|
Insulin B chain (9-23)
|
MHC
Insulin Receptor
IFNAR
|
Inflammation/Immunology
|
|
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
|
-
- HY-P10439
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
|
-
- HY-P10323
-
|
Tumstatin (74-98), human
|
Integrin
FAK
mTOR
Apoptosis
|
Cancer
|
|
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
|
-
- HY-P10323A
-
|
Tumstatin (74-98), human TFA
|
Integrin
FAK
mTOR
Apoptosis
|
Cancer
|
|
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
|
-
- HY-P5462A
-
|
|
Peptides
|
Inflammation/Immunology
|
|
PLP (180-199) TFA is the TFA salt form of PLP (180-199) (HY-P5462). PLP (180-199) TFA induces the activation and differentiation of T cells, and induces the experimental autoimmune encephalomyelitis (EAE) in mouse model .
|
-
- HY-P1837
-
|
|
Influenza Virus
HSV
|
Infection
|
|
Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K d to form a complex, which is then recognized by specific CD8 + T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8 + T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza .
|
-
- HY-P1997
-
|
Desferrichrome; DFC; N-Desferriferrichrome
|
Biochemical Assay Reagents
|
Others
|
|
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
|
-
- HY-P5396A
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P3742
-
|
|
Tyrosinase
MHC
|
Cancer
|
|
Tyrosinase (192-200), human mouse is a HLA-B*4403-restricted tyrosinase epitope with affinity for HLA-B4403 and HLA-B4402. Tyrosinase (192-200), human mouse binds to HLA-B*4403 to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402 donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .
|
-
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
-
- HY-159771
-
|
|
FAP
|
Cancer
|
|
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
|
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-P5442
-
|
|
Peptides
|
Others
|
|
MOG (44-54), mouse, human, rat is a biological active peptide. (minimal binding epitope for the CD8 + MOG‐specific T cell)
|
-
- HY-P10382
-
|
|
MHC
|
Inflammation/Immunology
|
|
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .
|
-
- HY-P5448
-
|
|
Peptides
|
Others
|
|
MOG (92–106), mouse, rat is a biological active peptide. (This is amino acids 92 to 106 fragment of the myelin oligodendrocyte glycoprotein (MOG) from mouse/rat. Mice with MOG (92–106)-induced experimental autoimmune encephalomyelitis develop extensive B cell reactivity against secondary myelin antigens. Despite the fact that this MOG peptide induces only weak T cell responses, MOG-induced autoimmunity is very severe. This peptide is encephalitogenic in SJL mice, DA rats, and rhesus monkeys.)
|
-
- HY-P10650
-
|
|
Ras
|
Cancer
|
|
FAM49B (190-198) mouse is a peptide fragment of FAM49B. FAM49B is a mitochondria-localized protein that regulates mitochondrial fission. FAM49B regulates mitochondrial function and integrity and tumor progression. FAM49B is also a negative regulator in T cell activation, it acts by repressing GTPase Rac activity and modulating cytoskeleton reorganization .
|
-
- HY-P5295
-
|
|
Fluorescent Dye
|
Others
|
|
Cy3-Ova (323-339) is an Cy3 labled OVA Peptide (323-339) (HY-P0286). Cy3 is a fluorescent dye belonging to the Cyanine family and is a fluorescent light product of Cy5. Cyanine is commonly used in fluorescence microscopy, cell imaging, and molecular biology experiments. OVA Peptide (323-339) represents the T and B cell epitopes of ovalbumin (OVA). OVA Peptide (323-339) has limited immunogenic efficacy in activating OVA-sensitized and attacked mouse spleen cells .
|
-
- HY-P10826
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
|
-
- HY-P10509
-
|
|
CMV
|
Infection
|
|
IE1 peptide refers to an antigenic peptide encoded by the immediate early (IE) gene of mouse cytomegalovirus (mCMV). IE1 peptide is one of the key antigenic peptides expressed during mCMV infection, plays a role in transcriptional activation in the life cycle of mCMV, and is one of the earliest genes expressed in the viral replication cycle. IE1 peptide is an important target for CD8+ T cell response and can be used to study the host immune response to mCMV infection .
|
-
- HY-P10393
-
|
ERα (295-311)
|
Apoptosis
|
Cancer
|
|
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .
|
-
- HY-P10492
-
|
|
Peptides
|
Others
Metabolic Disease
|
|
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-K0307
-
1 Publications Verification
|
|
MCE Mouse CD4+ T Cells Negative Selection Kit is designed for the isolation of CD4+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.
|
-
- HY-K0306
-
|
|
|
MCE Mouse CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.
|
-
- HY-K0309
-
|
|
|
MCE Mouse CD8+ T Cells Negative Selection Kit is designed for the isolation of CD8+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.
|
-
- HY-K0354
-
|
|
|
MCE Mouse CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
(5)
-
- HY-P99948
-
|
AMG-596
|
EGFR
CD3
|
Neurological Disease
Cancer
|
|
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
|
-
(5)
-
- HY-P990173
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
|
-
(5)
-
- HY-P990534
-
|
K1-70
|
TSH Receptor
|
Endocrinology
Cancer
|
|
Anti-TSHR Antibody (K1-70) is an anti-TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
|
-
(5)
-
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
|
|
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .
|
-
(5)
-
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
-
(5)
-
- HY-P99152
-
|
Muromanab-CD3
|
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
|
-
(5)
-
- HY-P990802
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
-
- HY-P990790
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
(5)
-
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
(5)
-
- HY-P99129
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
|
-
(5)
-
- HY-P990680
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
|
-
(5)
-
- HY-P990795
-
|
|
Osteopontin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
(5)
-
- HY-P99916
-
|
AMG-427
|
FLT3
CD3
TNF Receptor
|
Inflammation/Immunology
Cancer
|
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
|
-
(5)
-
- HY-P99124
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .
|
-
(5)
-
- HY-P99128
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
|
-
(5)
-
- HY-P99123
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Mouse CD28 Antibody (37.51) is an agonistic agonistic CD28-specific antibody derived from the host Syrian Hamster. Anti-Mouse CD28 Antibody (37.51) partially prevents lethal graft-versus-hostdisease (GVHD) by selective depletion of alloreactive T cells in mice .
|
-
(5)
-
- HY-P99141
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
|
-
(5)
-
- HY-P990303
-
|
|
Nuclear Factor of activated T Cells (NFAT)
|
Others
|
|
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry .
|
-
(5)
-
- HY-P990953
-
|
Gen1047
|
CD3
|
Cancer
|
|
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
|
-
(5)
-
- HY-P991193
-
|
|
TNF Receptor
|
Cancer
|
|
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
|
-
(5)
-
- HY-P99119
-
|
|
TNF Receptor
Bcl-2 Family
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
|
-
(5)
-
- HY-P990188
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research .
|
-
(5)
-
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
-
- HY-P990175
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
|
-
(5)
-
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
(5)
-
- HY-P991112
-
|
|
Transmembrane Glycoprotein
|
Infection
|
|
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
(5)
-
- HY-P99138
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonal antibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
|
-
(5)
-
- HY-P990820
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-4 Antibody (RMT4-53) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-53) can block T cell immunoglobulin and mucin domain 4 (TIM-4). Anti-Mouse TIM-4 Antibody (RMT4-53) can inhibit the engulfment of apoptotic cells and T cell proliferation. Anti-Mouse TIM-4 Antibody (RMT4-53) can be used for the researches of cancer, immunology and metabolic disease, such as MC38 tumor and graft .
|
-
(5)
-
- HY-P990285
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse CD200 Antibody (OX-90) is an anti-mouse CD200 IgG2a monoclonal antibody. Anti-Mouse CD200 Antibody (OX-90) can reduce immune cell infiltration and T cell function by blocking CD200. Anti-Mouse CD200 Antibody (OX-90) can be used for research on immunology .
|
-
(5)
-
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
(5)
-
- HY-P99382A
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy .
|
-
(5)
-
- HY-P990264
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4 +, CD8 + T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models .
|
-
(5)
-
- HY-P990124
-
|
|
TNF Receptor
NF-κB
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
-
- HY-P990262
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8 + T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD) .
|
-
(5)
-
- HY-P990287
-
|
|
CD1
|
Inflammation/Immunology
|
|
Anti-Mouse CD1d Antibody (19G11) is a rat-derived IgG1 type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (19G11) can neutralize CD1d and inhibit the activation of invariant natural killer T (iNKT) cells. Anti-Mouse CD1d Antibody (19G11) can be used for the researches of inflammation and immunology, such as colitis .
|
-
(5)
-
- HY-P990249
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
|
-
(5)
-
- HY-P990299
-
|
|
Phosphatase
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor .
|
-
(5)
-
- HY-P990237
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
|
-
(5)
-
- HY-P990250
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonal antibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
|
-
(5)
-
- HY-P990157
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonal antibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
|
-
(5)
-
- HY-P990279
-
|
|
CD276/B7-H3
Apoptosis
STAT
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
|
-
(5)
-
- HY-P990115
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
|
-
(5)
-
- HY-P99131
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse CD90.2 Antibody (30H12) is an anti-mouse CD90.2 IgG2b antibody inhibitor derived from host Rat. Anti-Mouse CD90.2 Antibody (30H12) can deplete innate lymphoid cells (ILC) and T cells. Anti-Mouse CD90.2 Antibody (30H12) can be used for the researches of infection, inflammation and immunology, such as Yersinia enterocolitica infection and airway inflammation .
|
-
(5)
-
- HY-P990261
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD83 Antibody (Michel-17) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD83. Anti-Mouse CD83 Antibody (Michel-17) can block CD83 and inhibit T cells proliferation. Anti-Mouse CD83 Antibody (Michel-17) can be used for the researches of cancer and immunology, such as solid tumor .
|
-
(5)
-
- HY-P990123
-
|
|
Transmembrane Glycoprotein
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
|
-
(5)
-
- HY-P990803
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
-
- HY-P990201
-
|
|
L-Selectin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonal antibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
|
-
(5)
- HY-P990180
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
|
-
(5)
- HY-P991307
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
-
(5)
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
-
(5)
- HY-P990149
-
|
|
Tyrosinase
|
Cancer
|
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human TYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8 + T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
|
-
(5)
- HY-P990179
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonal antibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
|
-
(5)
- HY-P990152
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse TIM-4 Antibody (RMT4-54) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-54) reacts with mouse T cell immunoglobulin and mucin domain 4 (TIM-4) and blocks TIM-4 signaling. Anti-Mouse TIM-4 Antibody (RMT4-54) inhibits phagocytosis of apoptotic cells. Anti-Mouse TIM-4 Antibody (RMT4-54) can be used for the researches of immunology and metabolic disease .
|
-
(5)
- HY-P99140
-
|
|
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse IL-1R Antibody (JAMA-147) is an anti-mouse IL-1R IgG2b antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IL-1R Antibody (JAMA-147) diminishes Spp1hi-TAM-mediated T cell suppression. Anti-Mouse IL-1R Antibody (JAMA-147) can be used for the researches of inflammation, metabolic disease and infection, such as diabetes .
|
-
(5)
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
(5)
- HY-P990205
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
|
-
(5)
- HY-P990159
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonal antibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
|
-
(5)
- HY-P99147
-
|
|
CD3
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) is an Armenian Hamster-derived IgG antibody inhibitor, targeting to mouse TCR V gamma 2. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) reacts with an epitope on the delta chain of the mouse Vγ2 TCR (V gamma 2 T cell receptor). Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can deplete γδ T cell. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can be used for the researches of infection and immunology, such as herpes simplex virus-1 (HSV-1) infection .
|
-
(5)
- HY-P990137
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-Rat CD28 Antibody (JJ319) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ319) activates T cells in the presence of T cell receptor-stimulation. Anti-Rat CD28 Antibody (JJ319) can be used for the researches of inflammation and immunology, such as transplantation and neuritis .
|
-
(5)
- HY-P990793
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD) .
|
-
(5)
- HY-P990154
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-1/CD365 Antibody (3B3) is a rat-derived IgG2a κ type agonistic antibody, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3B3) enhances T-cell proliferation and responses by forming a stable TIM-1 complex and bringing TIM-1 into the T-cell receptor (TCR)-CD3 complex. Anti-Mouse TIM-1/CD365 Antibody (3B3) can be used for the researches of cancer, inflammation and immunology, such as experimental autoimmune encephalomyelitis, B16 F10 tumor and transplant .
|
-
(5)
- HY-P990153
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse TIM-2 Antibody (RMT2-29) is a rat-derived Ig2a λ type antibody inhibitor, targeting to mouse TIM-2. Anti-Mouse TIM-2 Antibody (RMT2-29) reacts with mouse T cell immunoglobulin and mucin domain 2 (TIM-2) and blocks TIM-2 signaling. Anti-Mouse TIM-2 Antibody (RMT2-29) can be used for the research of immunology.
|
-
(5)
- HY-P990243
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonal antibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
|
-
(5)
- HY-P990292
-
|
|
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD132 (common γ chain) Antibody (3E12) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse CD132. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can block IL-2, IL-4 and IL-7. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can inhibit T cells and B cells. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can be used for the researches of cancer, immunology, inflammation and metabolic disease, such as tumor, skin transfer and diabetes .
|
-
(5)
- HY-P990142
-
|
|
MHC
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonal antibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
|
-
(5)
- HY-P990807
-
|
|
CD1
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD1d Antibody (20H2 (HB323)) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (20H2 (HB323)) can block CD1d and neutralize invariant natural killer
T (iNKT) cells. Anti-Mouse CD1d Antibody (20H2 (HB323)) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma, L. monocytogenes infection and arthritis .
|
-
(5)
- HY-P99123A
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
|
-
(5)
- HY-P990141
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonal antibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
|
-
(5)
- HY-P991328
-
|
|
Notch
|
Cancer
|
|
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
|
-
(5)
- HY-P990236
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
|
-
(5)
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
-
(5)
- HY-P990809
-
|
|
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is an agonistic mouse-derived IgG2a κ antibody, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can stimulate 4-1BB signaling and induce T cell mediated antitumor immunity. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease, such as glioblastoma and retrovirus infection .
|
-
(5)
- HY-P992061
-
|
|
CD3
Calcium Channel
|
Inflammation/Immunology
|
|
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes .
|
-
(5)
- HY-P992062
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 + T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .
|
-
(5)
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
(5)
- HY-P992056
-
|
|
Autophagy
|
Cancer
|
|
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 + T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 + T cells strictly depends on the presence of PILRα, and it does not affect CD4 + T cells or T cell development in the thymus, exhibiting high specificity .
|
-
(5)
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
(5)
- HY-P992352
-
|
|
|
|
|
ES005 is an anti-tumor compound and LAG3 inhibitor. ES005 blocks the interactions of LAG3 with MHC-II, LSECtin and FGL1, thereby effectively reversing the LAG3-mediated inhibition of T cell activation and NFAT reporter gene expression. ES005 exhibits significant tumor growth inhibitory effects in syngeneic mouse breast tumor models using humanized LAG3 knock-in mice. ES005 can be used for breast tumor-related research .
|
-
(5)
- HY-P991824
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- T cells and Foxp3 + regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
- HY-P992063
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody that binds to CD8α on mouse CD8 + T cells. When used in combination with a non-depleting anti-CD4 antibody, Anti-Mouse CD8α Antibody (YTS 105.18) does not deplete CD8 + T cells, but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used for research on graft rejection. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P991808
-
-
(5)
- HY-P991815
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD90.1 Antibody (OX-7) reacts with the mouse and rat CD90.1. CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels, T cells, neurons and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991820
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Anti-Mouse CD45 Antibody (I3/2.3) reacts with the mouse CD45. CD45 plays a key role in T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
- HY-P991802
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse TCR Beta Antibody (H57-597) reacts with the mouse TCRβ. Anti-Mouse TCR Beta Antibody (H57-597) can be used for the study of T cell-mediated diseases and transplant rejection. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
- HY-P991810
-
-
(5)
- HY-P991827
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
- HY-P991775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Anti-Rat CTLA-4 Antibody (WKH203) reacts with rat CTLA-4. Anti-Rat CTLA-4 Antibody (WKH203) binds to the CTLA-4 protein disrupts the key signaling mechanisms linked to the suppression of T cell activity, triggering T cells readily and enhancing the immune system’s capacity to identify and eliminate cancer. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991814
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse Ly-6C Antibody (7B10) reacts with the mouse Ly-6C. Ly-6C antigens are encoded by a complex multigene family and have primarily been defined as novel T cell-activating determinants. Recommend Isotype Controls: Armenian Hamster IgM .
|
-
(5)
- HY-P991765
-
|
|
VISTA
|
Inflammation/Immunology
|
|
Anti-VISTA Antibody (GG8) reacts with human VISTA. Endogenous VISTA has inhibitory effects both as a ligand on APCs and as a receptor on T cells. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991854
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-iNKT Cell Antibody (6B11) recognizes an epitope on T cell receptor (TCR) V alpha 24-J alpha 18. Anti-iNKT Cell Antibody is specific for cloned and primary human but not rodent iNKT and the human invariant TCR-α. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991958
-
|
|
CTLA-4
|
Cancer
|
|
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
|
-
(5)
- HY-P991777
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD86/B7-2 Antibody (2D10) reacts with mouse CD86 (B7-2). Anti-Mouse CD86/B7-2 Antibody (2D10) reduces IL-4 production in T cells. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
- HY-P991759
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD86 Antibody (OX-48) recognizes CD86, thereby blocking the binding of CD86 to CD28, and thus inhibiting T cell proliferation. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991761
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-Mouse CXCL10 Antibody (1F11) reacts with the pro-inflammatory CXCL10. Anti-Mouse CXCL10 Antibody (1F11) can be used for neutralization of CXCL10 (in vitro and in vivo) and for inhibition of T cell recruitment in vivo in a range of inflammatory disease models. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
- HY-P991829
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse TIM-1/CD365 Antibody (RMT1-10) reacts with mouse T cell immunoglobulin and mucin domain 1 (TIM-1). Anti-Mouse TIM-1/CD365 Antibody (RMT1-10) is effective in promoting allograft survival through blocking TIM-1. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
- HY-P992060
-
|
|
CD20
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8 + T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury .
|
-
(5)
- HY-P992005
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatory T cells in the tumor microenvironment, and activates effector T cells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
|
-
(5)
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
(5)
- HY-P990215
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-27 p28 Antibody (MM27.7B1) is a mouse-derived anti-mouse IL-27 p28 IgG2a, κ type antibody inhibitor. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) can neutralize IL-27. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) delays CD8+ T cell reconstitution mediated by IL-27 after murine anti-thymocyte globulin (mATG) treatment in BALB/c heart allografts mice models .
|
-
(5)
- HY-P990176
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonal antibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
|
-
(5)
- HY-P990822
-
|
|
Transmembrane Glycoprotein
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse TIM-1/CD365 Antibody (3D10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can block mouse T cell immunoglobulin and mucin domain 1 (TIM-1) also known as CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can be used for the researches of inflammation, immunology and cardiovascular disease, such as graft-versus-host disease (GVHD), airway inflammation and atherosclerosis .
|
-
(5)
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
(5)
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P990864
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
|
-
(5)
- HY-P99943
-
|
KN-046
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
|
-
(5)
- HY-P990281
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1 λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can deplete CD25+ T cells. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can be used for the researches of immunology and inflammation, such as atopic dermatitis .
|
-
(5)
- HY-P990161
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
|
-
(5)
- HY-P990255
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
|
-
(5)
- HY-P990254
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
|
-
(5)
- HY-P990113
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Rat TCR gamma/delta Antibody (V65) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat TCR gamma/delta. Anti-Rat TCR gamma/delta Antibody (V65) can deplete γδ T cells. Anti-Rat TCR gamma/delta Antibody (V65) can be used for the research of immunology .
|
-
(5)
- HY-P991336
-
|
INBRX-106; ES-102
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
|
-
(5)
- HY-P990187
-
|
|
MHC
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection .
|
-
(5)
- HY-P990203
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis .
|
-
(5)
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection .
|
-
(5)
- HY-P99144A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .
|
-
(5)
- HY-P991181
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .
|
-
(5)
- HY-P990004
-
|
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
|
-
(5)
- HY-P991353
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
|
-
(5)
- HY-P990160
-
|
|
MHC
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonal antibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
|
-
(5)
- HY-P99146
-
|
|
CD3
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonal antibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
|
-
(5)
- HY-P990304
-
|
|
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a rat-derived IgG2a κ antibody inhibitor, targeting to mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can block 4-1BB ligand (4-1BBL) and inhibit CD4 + and CD8 + T cells. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology, such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection and herpetic stromal keratitis (HSK) .
|
-
(5)
- HY-P990819
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-Rat CD28 Antibody (JJ316) is a mouse-derived agonistic IgG1 κ type antibody, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ316) can induce T cell proliferation. Anti-Rat CD28 Antibody (JJ316) can be used for the researches of inflammation, immunology and neurological disease, such as experimental autoimmune encephalomyelitis (EAE) and graft-versus-host disease (GvHD) .
|
-
(5)
- HY-P992043
-
|
ANK-101
|
Interleukin Related
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tolododekin alfa (ANK-101) is a drug conjugate that anchors and combines IL-12 with Aluminum Hydroxide (HY-B1521). Tolododekin alfa promotes the recruitment of effector CD8 + T cells to tumor sites, enhances the production of γ-interferon, upregulates the expression of PD-L1, and induces sustained pro-inflammatory gene expression in mouse tumor models. Tolododekin alfa can be used for research related to advanced solid tumors .
|
-
(5)
- HY-P990865
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonal antibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P990860
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1 κ chimeric agonistic antibody, targeting to human CD40. Anti-CD40 Antibody (G28.5) can activate CD40 signaling and promote anti-tumor T cell responses. Anti-CD40 Antibody (G28.5) can be used for the research of cancer, such as endometrial cancer .
|
-
(5)
- HY-P991461
-
|
XmAb968
|
CD38
|
Cancer
|
|
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
|
-
(5)
- HY-P990870
-
|
|
CD19
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P99976
-
|
|
CD19
|
Inflammation/Immunology
|
|
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells .
|
-
(5)
- HY-P990801
-
|
|
Integrin
Parasite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
|
-
(5)
- HY-P991481
-
|
|
CCR
|
Inflammation/Immunology
Cancer
|
|
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 + regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .
|
-
(5)
- HY-P990868
-
|
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
(5)
- HY-P990128
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD80/B7-1. Anti-Rat CD80/B7-1 Antibody (3H5) blocks a costimulatory signals for T-cell activation. Anti-Rat CD80/B7-1 Antibody (3H5) can be used for the researches of cancer and immunology .
|
-
(5)
- HY-P9996
-
|
LY3434172; IBI-318
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
|
-
(5)
- HY-P990869
-
|
|
CD1
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991961
-
|
|
CTLA-4
|
Cancer
|
|
REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
|
-
(5)
- HY-P990855
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
(5)
- HY-P991896
-
|
AT14-012
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-122808
-
-
-
- HY-N0600
-
-
-
- HY-112817
-
|
8-Oxo-Deoxyguanosine triphosphate
|
Microorganisms
Source Classification
|
Apoptosis
|
|
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
|
-
-
- HY-N16021
-
|
|
Structural Classification
Lipid
|
Toll-like Receptor (TLR)
Cdc42-binding kinase
Galectin
|
|
4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .
|
-
-
- HY-116640
-
-
-
- HY-111604
-
|
|
Marine natural products
Source Classification
|
Others
|
|
Turbinaric acid is a kind of secosqualene carboxylic acid. Turbinaric acid exhibits cytotoxicity against mouse melanoma cells and human colon cancer cells. Turbinaric acid can be used as a chemical marker for T. conoides. Turbinaric acid can be used for research on melanoma and colon cancer .
|
-
-
- HY-130757
-
|
|
Microorganisms
Xanthones
Phenols
Source Classification
|
Endogenous Metabolite
|
|
Remisporine B is a polyketide, that can be isolated from Penicillium sp. ZJ-SY2. Remisporine B exhibits immunosuppressive efficacy, that inhibits concanavalin A (HY-P2149)-induced T-cell proliferation and LPS (HY-D1056)- induced B-cell proliferations of mouse splenic lymphocytes with IC50 of 30.1 µg/mL and 32.4 µg/mL .
|
-
-
- HY-121619
-
-
-
- HY-N18070
-
|
|
Structural Classification
Euphorbia resinifera O. Berg
Terpenoids
Sesquiterpenes
Euphorbiaceae
Plants
Source Classification
|
Drug Derivative
PKC
Fungal
|
|
12-Deoxyphorbol-13-isobutyrate-20-acetate is a 12-deoxy-phorbol diterpene ester. 12-Deoxyphorbol-13-isobutyrate-20-acetate is a protein kinase C (PKC) agonist that activates protein kinase C to phosphorylate troponin I and troponin T. 12-Deoxyphorbol-13-isobutyrate-20-acetate induces skin irritation and necrosis in mice without cocarcinogenic activity. 12-Deoxyphorbol-13-isobutyrate-20-acetate inhibits Aspergillus carbonarius growth. 12-Deoxyphorbol-13-isobutyrate-20-acetate supports research on heart failure, cardiomyopathies and fungal infection .
|
-
-
- HY-N17771
-
|
|
Structural Classification
Impatiens balsamina Linn.
Balsaminaceae
Phenols
Polyphenols
Plants
Source Classification
|
Endogenous Metabolite
|
|
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC50=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC50 of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13757S
-
|
|
|
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
-
- HY-13757AS1
-
|
|
|
Tamoxifen-d3 is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-162874
-
|
|
|
DBCO
|
|
diABZI-V/C-DBCO is a STING agonist with an EC50 of 1.47 nM. diABZI-V/C-DBCO activates the STING pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B + CD8 + T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .
|
-
- HY-180200
-
|
|
|
Alkynes
|
|
RNK08954 is an orally active KRASG12D inhibitor with a Kd of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRASG12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRASG12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-150724
-
|
1018 ISS
|
|
CpG ODNs
|
|
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
|
-
- HY-154974
-
|
|
|
Cationic Lipids
|
|
LNP Lipid-8 (11-A-M) is an ionizable single-tail multi-head lipid that can be used as a lipid nanoparticle (LNP) to deliver siRNA to T cells without targeting ligands. LNP Lipid-8 is more selective for T cells than other cell types such as hepatocytes. LNP Lipid-8 selectively delivers siRNA/sgRNA to T cells (especially CD8+ T cells) through endogenous lipid transport pathways, and can enter cells and release RNA through endocytosis to achieve gene silencing. LNP Lipid-8 loaded with GFP siRNA (siGFP) significantly led to GFP gene silencing in mouse models. LNP Lipid-8 showed good efficacy and safety in both cells and animals, without obvious liver targeting and toxicity. LNP Lipid-8 can be used for RNA delivery research in the fields of tumor immunotherapy and T cell-mediated autoimmune diseases .
|
-
- HY-174612
-
|
|
|
mRNA
Interleukin & Receptors
|
|
Human IL27RA mRNA encodes the human interleukin 27 receptor subunit alpha (IL27RA) protein, a protein that is similar to the mouse T-cell cytokine receptor (Tccr) at the amino acid level. IL27RA is predicted to be a glycosylated transmembrane protein.
|
-
- HY-112817A
-
|
8-Oxo-Deoxyguanosine triphosphate trisodium
|
|
Nucleotide Analogs
Guanine Nucleotide
|
|
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
